Holen Sie sich die Stockscreener-App
23.07
5.87%
1.28
Handel nachbörslich:
22.40
-0.67
-2.90%
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? - The Motley Fool
Dyne therapeutics director Jason Rhodes sells $10.7m in stock - Investing.com UK
Dyne therapeutics director Jason Rhodes sells $10.7m in stock By Investing.com - Investing.com South Africa
Dyne Therapeutics(DYN.US) Director Sells US$10.71 Million in Common Stock - Moomoo
Form 4 Dyne Therapeutics Inc For: 30 June By Investing.com - Investing.com Canada
Atlas funds linked to Dyne (DYN) director sell 504,695 shares - Stock Titan
Myotonic Dystrophy Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma - Barchart.com
Form 144 Dyne Therapeutics For: 29 June By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics - The National Law Review
Form 144 Dyne Therapeutics For: 26 June By Investing.com - Investing.com Nigeria
Price to sales forward of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView
DYN Initiated Coverage by TD Cowen -- Rating Set to Buy - GuruFocus
Enterprise value to EBIT forward of Dyne Therapeutics Inc – BX:DYN - TradingView
Dyne therapeutics director Jason P Rhodes sells $5.65m in stock - Investing.com UK
Price to earnings forward of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Price to earnings forward of Dyne Therapeutics Inc – BX:DYN - TradingView
Form 4 Dyne Therapeutics Inc For: 26 June By Investing.com - Investing.com Australia
Enterprise value to revenue forward of Dyne Therapeutics Inc – BX:DYN - TradingView
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CFO sells 2,362 shares to cover taxes - Stock Titan
Dyne Therapeutics(DYN.US) Director Sells US$5.65 Million in Common Stock - Moomoo
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Dyne Therapeutics Insider Sold Shares Worth $5,646,497, According to a Recent SEC Filing - marketscreener.com
TD Cowen Initiates Dyne Therapeutics at Buy - Moomoo
TD Cowen Initiates Dyne Therapeutics(DYN.US) With Buy Rating - Moomoo
Dyne Therapeutics stock initiated at buy by TD Cowen on platform - Investing.com UK
Dyne Therapeutics stock initiated at buy by TD Cowen on platform By Investing.com - Investing.com Australia
Dyne Therapeutics (DYN) director-linked funds sell 267,760 shares - Stock Titan
Form 144 Dyne Therapeutics For: 25 June By Investing.com - Investing.com Nigeria
Dyne Therapeutics Inc Actuals & Estimates (NASDAQ:DYN) - TradingView
How (DYN) Movements Inform Risk Allocation Models - Stock Traders Daily
Erick Lucera files Form 144 to sell DYN shares (DYN) - Stock Titan
DYN Forecast — Price Target — Prediction for 2027 - TradingView
Dyne Therapeutics (DYN) Adds Barry Greene And Expands Funding, Is The Stock Still A Bargain? - Sahm
Dyne Therapeutics director Kersten sells $5.46 million in shares By Investing.com - Investing.com South Africa
Dyne Therapeutics director Kersten sells $5.46 million in shares - Investing.com UK
Form 4 Dyne Therapeutics Inc For: 24 June By Investing.com - Investing.com Nigeria
Form 144 Dyne Therapeutics For: 24 June By Investing.com - Investing.com South Africa
Dyne Therapeutics Insider Sold Shares Worth $5,464,611, According to a Recent SEC Filing - Moomoo
Dyne Therapeutics(DYN.US) Director Sells US$5.46 Million in Common Stock - Moomoo
Dyne Therapeutics (DYN) director-affiliated fund sells 263,962 shares under 10b5-1 plan - Stock Titan
3.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):